Micotil® (tilmicosin injection) is a proven, long-lasting Bovine Respiratory Disease (BRD) treatment that offers a flexible, cost-effective dose range for both metaphylaxis and individual pull-and-treat therapy. Micotil is indicated for the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida and Histophilus somni and for the control of respiratory disease in cattle at high risk of developing BRD associated with Mannheimia haemolytica.
Important safety information
Micotil Important Safety Information
See label for complete use information. Before using this product, it is important to read the entire product insert, including the boxed human warning
- Caution: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian
- Not for human use. Injection of this drug in humans has been associated with fatalities. Keep out of reach of children. Do not use in automatically powered syringes. Exercise extreme caution to avoid accidental self-injection. In case of human injection, consult a physician immediately and apply ice or cold pack to injection site while avoiding direct contact with the skin. Avoid contact with eyes.
- Always use proper drug handling procedures to avoid accidental self-injection. Consult your veterinarian on the safe handling and use of all injectable products prior to administration.
- For use in cattle or sheep only. Inject subcutaneously. Injection of this antibiotic has been shown to be fatal in swine and non-human primates, and may be fatal in horses and goats.
- Do not use in female dairy cattle 20 months of age or older. Use in lactating dairy cattle or sheep may cause milk residues.
- The following adverse reactions have been reported: in cattle: injection site swelling and inflammation, lameness, collapse, anaphylaxis/anaphylactoid reactions, decreased food and water consumption, and death.
- Micotil has a pre-slaughter withdrawal time of 42 days.
For Rumensin: Consumption by unapproved species or feeding undiluted may be toxic or fatal. Do not feed to veal calves.
- CAUTION: Federal law restricts medicated feed containing this veterinary feed directive (VFD) drug to use by or on the order of a licensed veterinarian.
- Cattle intended for human consumption must not be slaughtered within 28 days of the last treatment.
- To assure both food safety and responsible use, treatment must be initiated within the first 45 days of the production period. The treatment should not occur concurrent with or following administration of an injectable macrolide, or within 3 days following administration of a non-macrolide injectable BRD therapy.
- VFD expiration date must not exceed 45 days from the time of issuance. VFDs shall not be refilled.
- Use only in cattle fed in confinement for slaughter.
- Cattle with severe clinical illness should be evaluated for individual treatment with an alternative non-macrolide therapy.
- Do not use in female dairy cattle 20 months of age or older or in veal calves.
- Safety has not been established for cattle intended for breeding.
- Do not allow horses or other equines access to feeds containing tilmicosin.
- Avoid inhalation, oral exposure and direct contact with skin or eyes. Keep out of reach of children.
For all products: The labels contain complete use information, including cautions and warnings. Always read, understand and follow the labels and use directions.
Rumensin: Growing cattle on pasture or in drylot (stockers, feeders, and dairy and beef replacement heifers)
For increased rate of weight gain: Feed 50 to 200 mg/hd/d of monensin in at least 1.0 lb of Type C medicated feed. Or, after the 5th day, feed 400 mg/hd/d every other day in at least 2.0 lbs of Type C medicated feed. The Type C medicated feed must contain 25 to 400 g/ton of monensin (90% DM basis).
For the prevention and control of coccidiosis: Feed at a rate to provide 0.14 to 0.42 mg/lb of body weight/d of monensin up to a maximum of 200 mg/hd/d. The Type C medicated feed must contain 25 to 400 g/ton of monensin (90% DM basis).
Free-choice supplements: Approved supplements must provide not less than 50 nor more than 200 mg/hd/d of monesin.
Free choice supplements: Provide monensin at a rate of 50 to 200 mg/hd/d.
Rumensin: Mature reproducing beef cows
For improved feed efficiency when receiving supplemental feed: Feed continuously at a rate of 50 to 200 mg/hd/d of monensin. Cows on pasture or in drylot must receive a minimum of 1.0 lb of Type C medicated feed/hd/d. Do not self-feed.
For the prevention and control of coccidiosis: Feed at a rate of 0.14 to 0.42 mg/lb of body weight/d of monensin up to a maximum of 200 mg/hd/d.
For the control of Bovine Respiratory Disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida and Histophilus somni in groups of beef and non-lactating dairy cattle, where active BRD has been diagnosed in at least 10% of the animals in the group: Feed continuously for a single, 14-day period at 568 to 757 g/ton of tilmicosin (100% DM basis) in a Type C medicated feed as the sole ration to provide 12.5 mg/kg of body weight/day.
Administer one dose in the ear subcutaneously according to label directions.
Vaccine Precautions: Do not use Titanium BRSV 3, Titanium 3 LP, Titanium 3, Titanium IBR LP and Titanium IBR in pregnant cows or in calves nursing pregnant cows. Abortions may result.